412 related articles for article (PubMed ID: 22228883)
1. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Kircheis G; Lüth S
Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
[TBL] [Abstract][Full Text] [Related]
4. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
5. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
[TBL] [Abstract][Full Text] [Related]
6. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
7. Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
Ahn JO; Li Q; Lee YH; Han SM; Hwang CY; Youn HY; Chung JY
J Vet Sci; 2016 Sep; 17(3):431-3. PubMed ID: 26726023
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S
J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345
[TBL] [Abstract][Full Text] [Related]
9. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
Butterworth RF
Can J Gastroenterol Hepatol; 2019; 2019():8182195. PubMed ID: 31183339
[TBL] [Abstract][Full Text] [Related]
10. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
13. L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
Butterworth RF
Drugs; 2019 Feb; 79(Suppl 1):1-3. PubMed ID: 30706421
[No Abstract] [Full Text] [Related]
14. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
[TBL] [Abstract][Full Text] [Related]
15. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
[TBL] [Abstract][Full Text] [Related]
17. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
[TBL] [Abstract][Full Text] [Related]
18. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV
Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172
[TBL] [Abstract][Full Text] [Related]
19. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.
Weiss N; Tripon S; Lodey M; Guiller E; Junot H; Monneret D; Mayaux J; Brisson H; Mallet M; Rudler M; Imbert-Bismut F; Thabut D;
Fundam Clin Pharmacol; 2018 Apr; 32(2):209-215. PubMed ID: 29239015
[TBL] [Abstract][Full Text] [Related]
20. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
